Gluconex MR

Gliclazide

NIDD (type 2) in adults when dietary measures, physical exercise & wt loss alone are not sufficient to control blood glucose.

Adult 30-120 mg once daily. Dose may be increased to 60, 90 or 120 mg daily, if blood glucose is not adequately controlled in interval dose increment of at least 1 mth except in patients whose blood glucose has not reduced after 2 wk of treatment. In such case, may increase dose at the end of the 2nd wk of treatment. Max: 120 mg.

Should be taken with food: Preferably taken as a single dose at breakfast. Swallow whole tab.

Hypersensitivity to gliclazide, other sulfonylureas or sulphonamides. Type 1 diabetes. Diabetic pre-coma & coma, daibetic keto-acidosis. Treatment w/ miconazole. Severe renal or hepatic insufficiency. Lactation.

Hypoglycemia, especially during low-calorie diets, following prolonged or strenuous exercise, alcohol intake or if used in combination w/ hypoglycaemic agents. May increase risk of hypoglycaemia w/ patient refuses or (particularly in elderly subjects) is unable to cooperate; malnutrition, irregular mealtimes, skipping meals, periods of fasting or dietary changes; imbalance between physical exercise and carbohydrate intake; renal impairment; severe hepatic impairment; overdose; certain endocrine disorders eg, thyroid disorders, hypopituitarism & andrenal insufficiency, concomitant administration of certain other medicines. Poor blood glucose control. Careful monitoring of blood glucose in patients receiving a fluoroquinolone. Measurement of glycated Hb levels or fasting venous plasma glucose is recommended. Patients w/ G6PD deficiency. Avoid during pregnancy.

Hypoglycemia; GI disturbances including abdominal pain, nausea, vomiting, dyspepsia, diarrhea & constipation.

Increased hypoglycemic effect w/ possible onset of hypoglycemic symptoms or coma w/ miconazole (systemic route, oromucosal gel). Displaced binding to plasma proteins &/or reduced elimination w/ phenylbutazone (systemic route). Inhibited compensatory reactions w/ alcohol. Potentiation of the blood glucose lowering effect w/ other anti-diabetic agents (insulins, acarbose, metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists), β-blockers, fluconazole, ACE inhibitors (captopril, enalapril), H₂-receptor antagonists, MAOIs, sulphonamides, clarithromycin & non-steroidal anti-inflammatory agents. Diabetogenic effect of danazol. Increased blood glucose levels w/ chlorpromazine. Increased blood glucose levels w/ possible ketosis w/ glucocorticoids (intra-articular, cutaneous & rectal prep) & tetracosactrin. Increaed blood glucose levels due to β-2 agonist effects w/ ritodrine, salbutamol, terbutaline. Decreased exposure w/ St. John's wort. Dysglycemia w/ fluoroquinolones. Potentiation of anticoagulant therapy (warfarin).

Antidiabetic Agents

A10BB09 - gliclazide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.

Rx